Next Article in Journal
EPA/DHA Concentrate by Urea Complexation Decreases Hyperinsulinemia and Increases Plin5 in the Liver of Mice Fed a High-Fat Diet
Next Article in Special Issue
Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators
Previous Article in Journal
The Essential Oil of Cymbopogon citratus Stapt and Carvacrol: An Approach of the Antitumor Effect on 7,12-Dimethylbenz-[α]-anthracene (DMBA)-Induced Breast Cancer in Female Rats
Previous Article in Special Issue
Synthesis and Antimicrobial Activity of Novel 4-Hydroxy-2-quinolone Analogs
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 14
10.3390/molecules25143290
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Efficient Multicomponent Synthesis of Diverse Antibacterial Embelin-Privileged Structure Conjugates

by
Pedro Martín-Acosta
1,
Rosalyn Peña
1,
Gabriela Feresin
2,
Alejandro Tapia
2,
Isabel Lorenzo-Castrillejo
3,
Félix Machín
3,4,5,*,
Ángel Amesty
1,* and
Ana Estévez-Braun
1,*
1
Instituto Universitario de Bio-Orgánica Antonio González. Departamento de Química Orgánica. Universidad de La Laguna Avda. Astrofísico Fco. Sánchez N° 2, 38206 La Laguna, Spain
2
Instituto de Biotecnología-Instituto de Ciencias Básicas, Universidad Nacional de San Juan, Av. Libertador General San Martín 1109 (O), CP 5400 San Juan, Argentina
3
Unidad de Investigación Hospital Universitario Nuestra Señora de La Candelaria, 38010 Santa Cruz de Tenerife, Spain
4
Instituto de Tecnologías Biomédicas, Universidad de la Laguna, 38200 Tenerife, Spain
5
Facultad de Ciencias de la Salud, Universidad Fernando Pessoa Canarias, 35450 Las Palmas de Gran Canaria, Spain
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(14), 3290; https://doi.org/10.3390/molecules25143290
Submission received: 30 June 2020 / Revised: 17 July 2020 / Accepted: 17 July 2020 / Published: 20 July 2020
(This article belongs to the Special Issue Strategies toward Bioactive Natural Product Like-Compounds)
Browse Figures
Versions Notes

Abstract

:
A library of embelin derivatives has been synthesized through a multicomponent reaction from embelin (1), aldehydes and privileged structures such as 4-hydroxycoumarin, 4-hydroxy-2H-pyran-2-one and 2-naphthol, in the presence of InCl3 as catalyst. This multicomponent reaction implies Knoevenagel condensation, Michael addition, intramolecular cyclization and dehydration. Many of the synthesized compounds were active and selective against Gram-positive bacteria, including one important multiresistant Staphylococcus aureus clinical isolate. It was found how the conjugation of diverse privileged substructure with embelin led to adducts having enhanced antibacterial activities.

Graphical Abstract

1. Introduction

Natural products continue to play a pivotal role in the search for new therapeutic drug leads. They have inherent bioactivities and high bioavailability, probably because of their specific interactions with target macromolecules in living organisms. Thus, the chemical space defined by natural products may nicely overlap with biological space [1]. Therefore, structural motifs and core skeletons from bioactive natural products can serve for the synthesis of novel core skeletons with high biological relevancy. In this context, the natural benzoquinone embelin (1) is an attractive molecule since displays a good number of biological activities such as antimicrobial [2], inhibition of X-chromosome-linked inhibitor of apoptosis protein (XIAPS) [3], inhibition of mortalin-p53 interactions, and activation of p53 protein in tumor cells [4], inhibition of 5-lipoxygenase [5], antitumoral activity via activation of p38/JNK pathway [6] and antidiabetic activity [7].
Thus, this benzoquinone represents a good starting scaffold for the preparation of a structurally diverse collection of embelin derivatives. To assure the biological relevancy of this library we combine the use of privileged structures and complexity-generating reactions such as multicomponent reactions [8,9,10,11,12]. Privileged structures are defined as a single molecular framework able to provide a series of ligands for diverse receptors and have been extensively utilized in rational drug design owing to their potent biological activities [13]. Thus, from a domino Knoevenagel–Michael addition–cyclization–dehydration reaction using embelin (1), aldehydes and antibacterial privileged structural motifs as source of nucleophilic carbons, we can access to a library of dihydropyranbenzoquinones embedded with privileged substructures (Scheme 1). Moreover, this library may provide new compounds with great potency against both drug sensitive and drug-resistant Gram-positive and Gram-negative organisms.

2. Results and Discussion

We selected the following molecular frameworks frequently observed in natural products and synthetic drugs with antibacterial activity [14,15]: 4-hydroxy-2H-pyran-2-one (2), 4-hydroxycoumarin (3), and 2-naphthol (4).
Since in the presence of an aldehyde both the embelin and the mentioned compounds (2–4) having nucleophilic carbons can react to afford the corresponding quinone methide intermediate via Knoevenagel condensation, we calculated the Fukui function in order to explore, which one shows the highest nucleophilicity. Fukui function is one of the widely used local density functional descriptor to model chemical reactivity and site-selectivity [16]. The local (condensed) Fukui functions (fk+, fk−, fk0) are calculated using the procedure proposed by Yang and Mortier [17], employing equations such as fk+ = [q(N + 1) − q(N)] for nucleophilic attack; fk− = [q(N) − q(N − 1)] for electrophilic attack and fk0 = ½ [q(N + 1) − q(N − 1)] for radical attack, where N is the total numbers of electrons. When a molecule accepts electrons, the electrons tend to go to places were fk+ is large because it is at these locations that the molecule is most able to stabilize additional electrons. Therefore a molecule is susceptible of an electrophilic attack at sites where fk− is large. The calculated values of the Fukui function (fk−) are shown in Figure 1.
As we can see, compounds 2–4 show higher values of (f−) than embelin (1), which implies that the quinone methide intermediate is presumably formed from these compounds, and next the nucleophilic attack of embelin will take place on the more electrophilic α, β-unsaturated carbonyl, followed of intramolecular cyclization with loss of H2O to yield the corresponding conjugates (Scheme 2).
Furthermore, for assessing the molecular diversity of the devised molecular framework, electrostatic polar surface area of energy-minimized conformers as well as the isosurface diagram of each adduct (R=H) were obtained by the calculation of electrostatic polar potentials and electron density [18]. As shown in Scheme 2, these three conjugates have a distinguishable display of electrostatic polar surface area because of the differentiation in electronic properties of each privileged substructure. The further expansion of molecular diversity can be achieved via the introduction of various moieties at the dihydropyran such as aliphatic and aromatic groups with electron donating and electron withdrawing substituents.
First, we decided to study the multicomponent reaction of embelin, 4-hydroxy-6-methyl-2H-pyran-2-one (2) and 4-bromobenzaldehyde. We used different reaction conditions and several catalysts employed in multicomponent reactions of 1,3-dicarbonyl compounds such as EDDA [19], PTSA [20], Sc(OTf)3 [21], Yb(OTf)3 [22], and InCl3 [23]. Some results are shown in Table 1.
The use of ethylendiamine diacetate (EDDA) as an effective organocatalyst for the initial Knoevenagel condensation did not produce the desired adduct 3a (entries 1–3). When InCl3 (10 mol%) was used in EtOH under reflux compound 3a was obtained in low yield (32%, entry 4). The yield was improved when the reaction was carried out without solvent (52%, entry 5) at 120 °C. The use of other Lewis acids (entries 6 and 7) and p-toluenesulfonic acid (PTSA) (entry 8) under neat conditions at 120 °C, did not improved the yields. Increasing the load of InCl3 (20 mol%) gave higher yield (58%). We also carried out the multicomponent reaction without catalyst (entry 9) and adduct 3a was achieved in low yield (11%). Thus, we selected the reaction conditions of entry 10 and the scope of this multicomponent process was then assessed through the variation of diverse aromatic and aliphatic aldehydes (Table 2). Diversely substituted tricyclic embelin adducts (3a–3l) could be prepared in moderated yields, demonstrating the versatility of this domino process. As a general trend, the multicomponent reaction is tolerant to a large variety of aryl-substituted aldehydes with electron-donating and electron-withdrawing groups, and also the reaction proceeds with aliphatic aldehydes.
The reaction can be rationalized via the formation of a conjugated electron-deficient enone (A) through a Knoevenagel condensation of 2 and an aldehyde. The next step of this mechanism could involve a Michael addition of embelin (1) to the reactive quinone methide intermediate to yield the intermediate (B), which can undergo an intramolecular cyclization through carbonyl a to give the para-quinone adduct or through carbonyl b to yield the ortho-quinone adduct (Scheme 3).
The process is regioselective since only the 1,4-benzoquinone adduct is obtained. A plausible explanation for this regioselectivity is that the reaction takes place through a more electron deficient carbonyl moiety next to another carbonyl group. Two new fused rings next to the benzoquinone core and three σ bonds (two C-C σ bonds and one C-O σ bond) were formed in this multicomponent reaction. The regiosubstitution of the corresponding adducts was confirmed by the three-bond correlations detected in the HMBC spectrum and also by the 13C NMR values of the quinone carbonyls [10,11,12] (Supplementary Materials). The InCl3 would promote the generation of the key quinone methide through dehydration of the alcohol formed in the Knoevenagel condensation and furthermore it could activate the quinone methide intermediates A.
Next, we decided to synthesize more complex embelin adducts by reacting embelin (1), aldehydes and the privileged structure 4-hydroxycoumarin (4). These tetracyclic adducts (4a–4l) compared to adducts 3a–3l present an extension of the structure by the introduction of an aromatic ring fused to the 2H-pyran-2-one nucleus, which results very attractive for the establishment of structure–activity relationships after biological evaluation. The same reaction conditions for the synthesis of adducts 3a–3l were used. Table 3 shows the structures and the yields of the obtained conjugates (4a–4l). As we can see improved yields were achieved by using 4-hydroxycoumarin as nucleophile component in the initial Knoevenagel condensation.
The last series was synthesized using 2-naphthol as nucleophilic component, in this case the tetracyclic adducts do not present the lactone ring of the previous series and they were obtained with higher yields than those from 4-hydroxy-2H-pyran-2-one and 4-hydroxycoumarin (Table 4). The conjugates synthesized from the aliphatic aldehydes (5j–5l) were achieved with the lowest yields.
Since, the conjugation of embelin with other anti-bacterial moieties could provide new candidates with great potency against both drug sensitive and drug-resistant Gram-positive and Gram-negative organisms, all synthesized conjugates were tested for antimicrobial activity. The compounds had no effect on the growth of the assayed Gram-negative bacteria Escherichia coli and on the growth of the yeast Saccharomyces cerevisiae (MIC > 128 μM). By contrast, many compounds were selectively active against the three Gram-positive bacteria tested: the methicillin-sensitive Staphylococcus aureus (MSSA) ATCC25923 strain, the methicillin-resistant S. aureus NRS402 strain, which is also intermediate resistant to vancomycin (VISA), and the Enterococcus faecalis ATCC29212 strain (Table 5), and they were more active than embelin (1). This fact is interesting since bacterial infections, caused by Gram-positive pathogens such as Staphylococcus are account for the majority of opportunistic community-acquired and hospital-acquired infections.
As we can see, the less active compounds turned out to be the conjugates with the naphthalene scaffold since most of them have MIC > 128 M (entries 26–37). Thus, the presence of a 2H-pyran-2-one moiety seems to be important for the antibacterial activity. In the series from 4-hydroxy-2H-pyran-2-one good values were achieved with both aromatic and aliphatic substituents at the dihydropyran ring (entries 2–13). Embelin–coumarin conjugates with aliphatic substituents at the dihydropyran ring were inactive while those with aromatic substituents showed high activity. Regarding the influence of the nature of the substituents on the aromatic ring in the activity, in the series from 4-hydroxy-6-methyl-2H-pyran-2-one, halogen substituents in para position afforded the lowest MIC values (entries 2–4). In the embelin–coumarin series the best results were obtained with 4-fluorphenyl and 3,4-dimetoxyphenyl groups (entries 4 and 8).

3. Materials and Methods

3.1. General Methods

Commercial reagents were purchased from Sigma-Aldrich (Darmstadt, Germany) and Alfa Aesar (Lancashire, UK) and were used without further purification. Analytical thin-layer chromatography was performed on Polygram SIL G/UV254 silica gel plates and chromatograms were visualized under UV light (254 and 360 nm). Pre-coated TLC plates SIL G-100 UV254 (Macherey–Nagel) and SILICA GEL GF plates (1000 μm, Analtech) were used for preparative TLC purification. 1H and 13C NMR spectra were acquired in CDCl3 (0.03% v/v TMS) DMSO-d6 or C6D6 at room temperature using Bruker Avance instruments (Bruker, Billarica, MA, USA) (400 or 500 MHz for 1H NMR and 100 or 125 MHz for 13C NMR). Chemical shifts are reported in parts per million (ppm). For 1H NMR data are reported in the following manner: Chemical shift (integration, multiplicity, coupling constant where applicable). The following abbreviations are used: s (singlet), br (broad), d (doublet), t (triplet), dd (double doublet), td (triplet of doublets), and m (multiplet). Coupling constants (J) are given in Hertz (Hz). 13C NMR were obtained with complete proton decoupling. MS and HRMS data were recorded in a VG Micromass ZAB-2F spectrometer and an ESI instrument LCT Premier XE Micromass (ESI-TOF). IR spectra were recorded on a Bruker IFS 28/55 spectrophotometer. All compounds were named using the ACD40 Name-Pro program, which is based on IUPAC rules. The embelin (1) used in the reactions was obtained from Oxalis erythrorhiza Gillies ex Hook. & Arn. following the procedure described in reference [24].

3.2. General Procedures for the Multicomponent Reaction between Embelin (1), Aldehyde (2), and 4-Hydroxy-6-Methyl-2-Pyrone (3), with Indium Trichloride as Catalyst

Embelin (1) (20.0 mg, 0.068 mmol), the corresponding aldehyde (2) (0.068 mmol), and 4-hydroxy- 6-methyl-2-pyrone (3) (1.0 mmol) were grinded in a mortar for 5 min. Then, 3.1 mg of InCl3 (20 mol %) was added and the reaction mixture was grinded again for 15 min, placed in a sealed tube and kept in an oven at 120 °C for 1.5 h. The resulting crude was purified by preparative-TLC chromatography using hexanes: EtOAc (3:2) as eluant.

3.3. 10-4(4-bromophenyl)-8-hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3a)

Following the general procedure described above, 22.4 mg (58%) of 3a were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 0.91 (3H, t, J = 6.2 Hz), 1.28 (16H, bs), 1.38 (3H, s), 1.60 (2H, m), 2.55 (2H, t, J = 8.9 Hz), 4.78 (1H, s), 5.27 (1H, s), 7.09 (2H, d, J = 8.2 Hz), 7.18 (2H, d, J = 8.1 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.0 (CH3), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.6 (CH2x3), 29.7 (CH2 x2), 31.9 (CH2), 32.9 (CH), 98.6 (CH), 101.9 (C), 117.5 (C), 120.0 (C), 121.9 (C), 130.3 (CHx2), 131.7 (CHx2), 140.0 (C), 148.1 (C), 158.8 (C), 158.9 (C), 162.2 (C), 162.9 (C), 179.4 (C), 182.2 (C). EIMS m/z (%): 568 (M+, 0.93), 510 (8), 509 (16), 508 (34), 429 (23), 428 (17), 427 (24), 415 (17), 413 (96), 412 (M+-C6H4Br, 38), 368 (8), 367 (15); HREIMS: 568.1483 (calcd for C30H33O679Br (M+) 568.1461); 570.1445 (calcd for C30H33O681Br (M+) 568.1441); IR (CHCl3) νmax 2923, 1698, 1651, 1626, 1594, 1487, 1383, 1318, 1211, 1173, 1125, 1074, 1037, 993 cm−1.

3.4. 10-(4-chlorophenyl)-8-hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3b)

Following the general procedure described above, 17.1 mg (48%) of 3b were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 0.91 (3H, t, J = 5.9 Hz), 1.28 (16H, bs), 1.38 (3H, s), 1.60 (2H, m), 2.55 (2H, t, J = 8.0 Hz), 4.80 (1H, s), 5.27 (1H, s), 6.65 (1H, bs), 7.02 (2H, d, J = 8.3 Hz), 7.16 (2H, d, J = 8.6 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.0 (CH2), 29.3 (CH2x2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 32.8 (CH), 98.4 (CH), 102.0 (C), 117.6 (C), 119.9 (C), 128.8 (CHx2), 130.1 (CHx2), 133.7 (C), 139.5 (C), 147.8 (C), 151.1 (C), 158.6 (C), 161.9 (C), 162.9 (C), 179.4 (C), 181.5 (C); EIMS m/z (%): 524 (M+, 0.96), 415 (22), 414 (42), 413 (M+-C6H4Cl, 100), 412 (42), 384 (30), 383 (44), 299 (11), 287 (16), 285 (36), 275 (22), 274 (79), 273 (45); HREIMS: 524.1931 (calcd for C30H33O635Cl (M+) 524.1966), 526.1940 (calcd for C30H33O637Cl (M+) 526.1936); IR (CHCl3) νmax 2923, 1698, 1626, 1596, 1318, 1209, 1125, 1092, 1038, 992, 973, 807, 653 cm−1.

3.5. 10-(4-fluorophenyl)-8-hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3c)

Following the general procedure described above, 14.5 mg (42%) of 3c were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ 0.91 (3H, t, J = 5.7 Hz), 1.28 (16H, bs), 1.37 (3H, s), 1.58 (2H, m), 2.54 (2H, t, J = 8.4 Hz), 4.84 (1H, s), 5.28 (1H, s), 6.71 (2H, t, J = 8.0 Hz), 7.22 (2H, m); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.0 (CH2), 29.3 (CH2x2), 29.5 (CH2), 29.6 (CH2 x3), 31.9 (CH2), 32.6 (CH), 98.4 (CH), 102.2 (C), 115.6 (CHx2, JC-F = 21.4 Hz), 117.8 (C), 119.9 (C), 130.3 (CHx2, JC-F = 8.13 Hz), 136.8 (C, JC-F = 2.3 Hz), 147.7 (C), 151.0 (C), 158.5 (C), 161.9 (C), 162.2 (C, JC-F = 245.8 Hz), 162.9 (C), 179.5 (C), 181.5 (C); EIMS m/z (%): 508 (M+, 100), 415 (5), 414 (M+-C6H4F, 26), 413 (64), 412 (34), 368 15), 367 (35), 314 (27), 313 (12), 285 (26), 275 (12), 274 (53), 272 (26), 271 (25), 257 (15); HREIMS: 508.2251 (calcd. for C30H33O6F (M+) 508.2261); IR (CHCl3) νmax 2929, 2857, 1701, 1655, 1629, 1598, 1511, 1387, 1322, 1214, 1175, 1128, 1042, 998, 837, 817, 747 cm−1.

3.6. 10-(3-fluorophenyl)-8-Hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3d)

Following the general procedure described above, 16.6 mg (48%) of 3d were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ: 0.87 (3H, t, J = 6.4 Hz), 1.24 (16H, bs), 1.45 (2H, m), 2.26 (3H), 2.44 (2H, m), 4.93 (1H, s), 6.19 (1H, s), 6.92 (1H, m), 7.03 (1H, m), 7.14 (1H, m), 7.25 (1H, m); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.0 (CH2), 29.3 (CH2x2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 33.0 (CH), 98.4 (CH), 101.9 (C), 114.8 (CH, JC-F = 21.1 Hz), 115.8 (CH, JC-F = 21.9 Hz), 124.4 (CH, JC-F = 2.3 Hz), 130.1 (CH, JC-F = 8.2 Hz), 117.5 (C), 119.9 (C), 143.3 (C, JC-F = 5.8 Hz), 147.9 (C), 151.1 (C), 158.7 (C), 161.9 (C), 162.9 (C, JC-F = 246.0 Hz), 163.0 (C), 179.4 (C), 181.4 (C); EIMS m/z (%): 508 (M+, 100), 415 (24), 414 (M+-C6H4F, 33), 413 (82), 369 (12), 368 (31), 367 (39), 285 (14), 274 (26); HREIMS: 508.2236 (calcd for C30H33O6F(M+) 508.2261); IR (CHCl3) νmax 2926, 2854, 1699, 1625, 1623, 1596, 1446, 1382, 1318, 1206, 1122, 1039, 994, 973, 823 cm−1.

3.7. 10-(4-nitrophenyl)-8-Hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3e)

Following the general procedure described above, 14.9 mg (41%) of 3e were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ: 0.91 (3H, t, J = 5.6 Hz), 1.27 (16H, bs), 1.40 (3H, s), 1.62 (2H, m), 2.57 (2H, bt, J = 9.2 Hz), 4.77 (1H, s), 5.27 (1H, s), 6.69 (1H, s), 7.11 (2H, d, J = 7.8 Hz), 7.72 (2H, d, J = 7.7 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.2 (CH3), 22.7 (CH2 x2), 28.0 (CH2), 29.3 (CH2x2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 33.5 (CH), 98.4 (CH), 101.2 (C), 116.8 (C), 120.4 (C), 123.9 (CHx2), 129.9 (CHx2), 147.1 (C), 147.8 (C), 148.2 (C), 151.2 (C), 158.9 (C), 161.7 (C), 163.6 (C), 179.1 (C), 181.4 (C); EIMS m/z (%) 535 (M+, 100), 415 (15), 414 (29), 413 (M+-C6H4O2N, 78), 397 (12), 396 (33), 395 (38), 382 (11), 324 (13), 285 (12), 274 (23), 273 (16), 271 (12); HREIMS: 535.2215 (calcd for C30H33O8N(M+) 535.2206); IR (CHCl3) νmax: 2926, 2855, 2287, 2166, 1719, 1626, 1591, 1518, 1443, 1382, 1343, 1326, 1216, 1171, 1125, 993, 780 cm−1.

3.8. 10-(3-fluoro-4-methoxyphenyl)-8-Hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3f)

Following the general procedure described above, 20.5 mg (56 %) of 3f were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ: 0.91 (3H, t, J= 5.4 Hz), 1.28 (16H, bs), 1.38 (3H, s), 1.58 (2H, m), 2.54 (2H, t, J = 7.8 Hz), 3.17 (3H, s), 4.87 (1H, s), 5.27 (1H, s), 6.41 (1H, t, J = 9.5 Hz), 7.16 (1H, s), 7.24 (1H, d, J = 10.4 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.1 (CH3), 22.6 (CH2x2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2 x3), 31.9 (CH2), 32.3 (CH), 56.2 (CH3), 98.5 (CH), 102.1 (C), 113.3 (CH, JC-F = 0.8 Hz), 116.3 (CH, JC-F = 18.7 Hz), 117.5 (C), 119.9 (C), 124.6 (CH, JC-F = 8.6 Hz), 133.9 (C), 147.2 (C, JC-F = 9.7 Hz), 147.8 (C), 151.2 (C), 153.6 (C), 158.6 (C), 163.2 (C, JC-F = 247.6 Hz), 162.8 (C), 179.4 (C), 181.6 (C); EIMS m/z (%) 538 (M+, 100), 415 (4), 414 (18), 413 (M+-C7H6OF, 21), 412 (14), 397 (33), 287 (17), 285 (18), 274 (30), 271 (13); HREIMS 538.2360 (calcd for C31H35O7F(M+) 538.2367); IR (CHCl3) νmax 2927, 2856, 1705, 1628, 1600, 1519, 1446, 1386, 1323, 1277, 1216, 1123, 1034, 998, 817 cm−1.

3.9. 10-(3,4-dimethoxyphenyl)-8-hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3g)

Following the general procedure described above, 14.2 mg (38 %) of 3g were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ 0.91 (3H, t, J = 6.3 Hz), 1.28 (16H, bs), 1.39 (3H, s), 1.60 (2H, m), 2.56 (2H, t, J = 2.8 Hz), 3.30 (3H, s), 3.47 (3H, s), 4.96 (1H, s), 5.34 (1H, s), 6.48 (1H, d, J = 8.2 Hz), 6.80 (1H, dd, J = 8.1, 1.3 Hz), 7.27 (1H, s); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.0 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 32.7 (CH), 55.8 (CH3), 56.1 (CH3), 98.4 (CH), 102.5 (C), 111.2 (CH), 112.5 (CH), 118.1 (C), 119.7 (C), 120.5 (CH), 133.7 (C), 147.6 (C), 148.7 (C), 148.9 (C), 151.0 (C), 158.3 (C), 162.1 (C), 162.5 (C), 179.7 (C), 181.6 (C); EIMS m/z (%): 550 (M+, 100), 415 (10), 414 (27), 413 (M+-C8H9O2, 14), 410 (21), 299 (11), 284 (12), 274 (36), 270 (10); HREIMS 550.2582 (calcd for C32H38O8 (M+) 550.2567); IR (CHCl3) νmax 2925, 2854, 1726, 1654, 1625, 15933, 1514, 1447, 1325, 1267, 1217, 1124, 1027, 993, 823 cm−1.

3.10. 10-(benzo[d][1,3]dioxo-5-yl)-8-hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3h)

Following the general procedure described above, 12.3 mg (34 %) of 3h were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.02 (3H, t, J = 5.5 Hz), 1.39 (16H, bs), 1.47 (3H, s), 1.67 (2H, m), 2.63 (2H, bt, J = 7.4 Hz), 4.96 (1H, s), 5.29 (2H, d, J = 11.6 Hz), 5.4 (1H, s), 6.70 (1H, d, J = 7.6 Hz), 6.91 (1H, d, J = 7.6 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.0 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2x2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x2), 31.9 (CH2), 32.8 (CH), 98.5 (CH), 101.2 (CH2), 102.4 (C), 108.3 (CH), 109.2 (CH), 122.2 (CH), 117.9 (C), 119.8 (C), 134.9 (C), 147.2 (C), 147.6 (C), 147.9 (C), 151.2 (C), 158.4 (C), 162.0 (C), 162.6 (C), 179.6 (C), 181.8 (C); EIMS m/z (%): 534 (M+, 100), 415 (18), 414 (41), 413 (M+-C7H5O2, 20), 412 (24), 397 (4), 393 (36), 380 (4), 287 (12), 284 (19), 283 (15), 274 (60), 273 (16); HREIMS 534.2295 (calcd for C31H34O8 (M+) 534.2254); IR (CHCl3) νmax 2924, 2853, 1726, 1624, 1591, 1486, 1442, 1325, 1217, 1125, 1036, 994, 806, 643 cm−1.

3.11. 8-Hydroxy-3-methyl-10-phenyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3i)

Following the general procedure described above, 17.6 mg (53 %) of 3i were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ: 0.91 (3H, t, J = 6.9 Hz), 1.28 (16H, bs), 1.35 (3H, s), 1.56 (2H, m), 2.52 (2H, m), 4.95 (1H, s), 5.28 (1H, s), 6.95 (1H, m), 7.07 (2H, t, J = 7.0 Hz), 7.44 (2H, d, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 20.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2 x2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x2), 31.9 (CH2), 33.2 (CH), 98.4 (CH), 102.4 (C), 118.0 (C), 119.7 (C), 127.8 (CH), 128.7 (CH), 140.9 (C), 147.8 (C), 151.1 (C), 158.5 (C), 161.9 (C), 162.6 (C), 179.6 (C), 181.6 (C); EIMS m/z (%) 490 (M+, 100), 415 (13), 414 (24), 413 (M+-C6H5, 74), 412 (13), 351 (17), 350 (27), 349 (10), 285 (17), 274 (27), 273 (20), 271 (13), 270 (14); HREIMS 490.2346 (calcd para C30H34O6 (M+) 490.2355); IR (CHCl3) νmax 2927, 2856, 1701, 1655, 1628, 1599, 1451, 1386, 1322, 1211, 1175, 1127, 1040, 998, 813, 703 cm−1.

3.12. 10-Hexyl-8-hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3j)

Following the general procedure described above, 8.6 mg (20%) of 3j were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 0.85 (6H, m), 1.01 (2H, m), 1.25 (20H, bs), 1.47 (2H, t, J = 7.0 Hz), 1.67 (2H, m), 1.85 (2H, t, J = 8.8 Hz), 2.27 (3H, s), 2.46 (2H, t, J = 6.9 Hz), 4.02 (1H, t, J = 6.1 Hz), 6.09 (1H, s); 13C NMR (100 MHz, CDCl3) δ 13.9 (CH3), 14.1 (CH3), 19.9 (CH3), 22.6 (CH2), 22.7 (CH2), 25.1 (CH2), 27.4 (CH), 28.0 (CH2), 29.2 (CH2), 29.3 (CH2 x2), 29.4 (CH2x2), 29.5 (CH2), 29.6 (CH2x2), 31.7 (CH2), 31.9 (CH2), 32.4 (CH2), 98.5 (CH), 101.6 (C), 118.2 (C), 119.6 (C), 149.5 (C), 151.5 (C), 160.0 (C), 162.2 (C), 162.5 (C), 179.2 (C), 182.0 (C); EIMS m/z (%) 498 (M+, 0.10), 415 (15), 414 (31), 413 (M+-C6H13, 100), 385 (6), 287 (4), 274 (11); HREIMS: 498.2990 (calcd. for C30H42O6 (M+) 498.2981); IR (CHCl3) νmax 2923, 2854, 1720, 1623, 1588, 1443, 1399, 1330, 1221, 1116, 1028, 964, 825, 651 cm−1.

3.13. 8-Hydroxy-3-methyl-10-propyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3k)

Following the general procedure described above, 6.2 mg (20%) of 3k were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ: 0.87 (6H, t, J = 6.0 Hz), 1.25 (16H), 1.47 (2H, m), 1.68 (2H, m), 1.82 (2H, m), 2.27 (3H, s), 2.45 (2H, t, J = 6.7 Hz), 4.02 (1H, bs), 6.09 (1H, s); 13C NMR (100 MHz, CDCl3) δ 13.9 (CH3), 14.1 (CH3), 18.4 (CH2), 20.0 (CH3), 22.6 (CH2), 22.7 (CH2), 27.4 (CH), 28.1 (CH2), 29.3 (CH2x2), 29.6 (CH2x4), 31.9 (CH2), 34.7 (CH2), 98.5 (CH), 101.7 (C), 118.2 (C), 128.8 (C), 130.9 (C), 149.5 (C), 160.1 (C), 162.2 (C), 162.5 (C), 179.4 (C), 182.4 (C). EIMS m/z (%): 456 (M+, 0.03), 416 (3), 415 (15), 414 (21), 413 (M+-C3H7, 100), 273 (5). HREIMS 456.2517 (calcd. for C27H36O6 (M+) 456.2512); IR (CHCl3) νmax 2924, 2854, 1712, 1624, 1592, 1445, 1398, 1330, 1214, 1168, 1114, 1036, 969, 812 cm−1.

3.14. 10-ethyl-8-Hydroxy-3-methyl-7undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione (3l)

Following the general procedure described above, 7.5 mg (25%) of 3l were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ 0.74 (3H, t, J = 7.5 Hz), 0.87 (3H, t, J = 6.3 Hz), 1.25 (16H, bs), 1.47 (2H, t, J = 8.6 Hz), 1.75 (1H, m), 1.95 (1H, m), 2.27 (3H, s, Me-3), 2.46 (2H, t, J = 7.4 Hz), 4.04 (1H, t, J = 4.3 Hz), 6.09 (1H, s), 7.13 (1H, s); 13C NMR (100 MHz, CDCl3) δ 9.0 (CH3), 14.1 (CH3), 20.0 (CH3), 22.6 (CH2), 22.7 (CH2), 24.8 (CH2), 28.1 (CH2), 28.2 (CH), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2x2), 29.6 (CH2x2), 31.9 (CH2), 98.5 (CH), 100.9 (C), 117.6 (C), 119.6 (C), 149.7 (C), 151.0 (C), 160.2 (C), 162.3 (C), 162.5 (C), 179.4 (C), 182.4 (C); EIMS m/z (%) 442 (M+, 1), 416 (5), 415 (14), 414 (33), 413 (M+-C2H5, 100), 385 (4), 287 (4), 275 (5), 274 (12); HREIMS: 442.2349 (calcd for C26H34O6 (M+) 442.2355); IR (CHCl3) νmax 2924, 2854, 1721, 1623, 1587, 1446, 1399, 1324, 1260, 1219, 1160, 1111, 1018, 984, 824 cm−1.

3.15. General Procedures for the Multicomponent Reaction between Embelin (1), Aldehyde (2), And 4-Hydroxycoumarin (4), With Indium Trichloride as Catalyst

Embelin (1) (20.0 mg, 0.068 mmol), the corresponding aldehyde (2) (0.068 mmol), and 4-hydroxycoumarin (4) (1.0 mmol) were grinded in a mortar for 5 min. Then, 3.1 mg of InCl3 (20 mol %) was added and the reaction mixture was grinded again for 15 min, placed in a sealed tube and kept in an oven at 120 °C for 1.5 h. The resulting crude was purified by preparative-TLC chromatography using toluene: EtOAc (9:1) as eluant.

3.16. 7-(4-bromophenyl)-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4a)

Following the general procedure described above, 28.7 mg (70 %) of 4a were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 4.7 Hz), 1.44 (16H, bs), 1.83 (2H, t, J = 7.4 Hz), 2.77 (2H, d, J = 4.6 Hz), 5.1 (1H, s), 6.83 (1H, s), 6.99 (1H, t, J = 7.5 Hz), 7.04 (2H, d, J = 8.2 Hz), 7.10 (1H, t, J = 6.9 Hz), 7.25 (2H, d, J = 7.8 Hz), 8.17 (2H, d, J = 7.5 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 22.7 (CH3x2), 28.1 (CH2, C-15), 29.3 (CH2x2), 29.4 (CH2), 29.5 (CH2), 29.7 (CH2x2), 31.9 (CH2), 33.5 (CH), 104.7 (C), 113.2 (C), 116.9 (CH), 117.5 (C), 120.2 (C), 122.1 (C), 123.4 (CH), 124.9 (CH), 130.7 (CH x2), 131.9 (CHx2), 133.2 (CH), 139.5 (C), 147.6 (C), 151.2 (C), 152.7 (C), 154.4 (C), 160.3 (C), 179.4 (C), 181.7 (C); EIMS m/z (%) 606 (M+, 100), 604 (M+, 90), 466 (21), 464 (28), 451 (11), 448 (35), 321 (35); HREIMS: 606.1441 (calcd for C33H33O681Br (M+) 606.1440), 604.1458 (calcd for C33H33O679Br (M+) 606.1461); IR (CHCl3) νmax 3343, 2923, 2852, 1719, 1639, 1609, 1527, 1490, 1457, 1378, 1332, 1289, 1182 cm−1.

3.17. 7-(4-chlorophenyl)-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4b)

Following the general procedure described above, 19.0 mg (50%) of 4b were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 5.5 Hz), 1.49 (16H, bs), 1.83 (2H, t, J = 8.1 Hz), 2.77 (2H, d, J = 4.4 Hz), 5.1 (1H, s), 6.81 (1H, s), 6.99 (1H, t, J = 7.1 Hz), 7.04 (1H, d, J = 8.0 Hz), 7.10 (1H, t, J = 7.6 Hz), 7.19 (2H, d, J = 7.8 Hz), 7.32 (2H, d, J = 7.9 Hz), 8.17 (1H, d, J = 7.8 Hz); 13C NMR (150 MHz, (CD3)2SO) δ 14.4 (CH3), 22.5 (CH2), 22.8 (CH2), 28.5 (CH2), 29.2 (CH2), 29.5 (CH2x2), 29.5 (CH2x2), 29.7 (CH2), 31.7 (CH2), 33.6 (CH), 104.9 (C), 113.7 (C), 115.9 (C), 116.9 (CH), 117.1 (C), 123.1 (CH), 125.4 (CH), 128.6 (CHx2), 131.1 (CHx2), 132.2 (CH), 133.5 (C), 141.4 (C), 148.6 (C), 148.7 (C), 152.4 (C), 154.4 (C), 160.3 (C), 176.4 (C), 184.1 (C); EIMS m/z (%) 560 (M+, 100), 562 (M+, 41), 450 (38), 449 (75), 448 (48), 419 (51), 320 (35), 310 (87); HREIMS 560.1990 (calcd for C33H33O635Cl (M+) 560.1966), 562.1977 (calcd for C33H33O637Cl (M+) 562.1936); IR (CHCl3) νmax 3338, 2925, 2854, 1719, 1640, 1611, 1492, 1458, 1395, 1335, 1291, 1231, 1182, 1046 cm−1.

3.18. 7-(4-fluorophenyl)-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4c)

Following the general procedure described above, 20.3 mg (55 %) of 4c were obtained as an amorphous violet solid 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 5.4 Hz), 1.48 (16H, bs), 1.82 (2H, t, J = 7.1 Hz), 2.77 (2H, d, J = 6.6 Hz), 5.13 (1H, s), 6.89 (2H, t, J = 8.0 Hz), 7.01 (4H, m, J = 8.4, 5.5 Hz), 7.09 (1H, d, J = 7.5 Hz), 8.18 (1H, d, J = 7.5 Hz);13C NMR (100 MHz, CDCl3) δ: 14.1 (CH3), 22.7 (CH2x2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2x2), 31.9 (CH2), 33.2 (CH), 104.9 (C), 113.2 (C), 115.7 (CH, JC-F = 21.7 Hz), 116.9 (CH), 117.7 (C), 120.0 (C), 123.2 (CH), 124.8 (CH), 128.9 (C), 130.5 (CH, JC-F = 8.3 Hz), 133.0 (CH), 136.6 (C), 147.6 (C), 152.6 (C), 154.3 (C), 160.2 (C), 162.2 (C, JC-F = 246.1 Hz), 179.4 (C), 181.7 (C); EIMS m/z (%) 544 (M+, 68), 449 (81), 404 (30), 307 (39), 309 (100), 337 (39), 295 (11); HREIMS 544.2274 (calcd for C33H33O6F (M+) 544.2261); IR (CHCl3) νmax 2924, 2853, 1712, 1636, 1609, 1561, 1508, 1458, 1329, 1294, 1230, 1186, 1050 cm−1.

3.19. 7-(3-fluorophenyl)-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4d)

Following the general procedure described above, 18.9 mg (51 %) of 4d were obtained as an amorphous violet solid. 1H NMR (500 MHz, C6D6) δ: 1.11 (3H, t, J = 6.6 Hz), 1.49 (16H, bs), 1.79 (2H, t, J = 6.9 Hz), 2.74 (2H, m), 5.16 (1H, s), 6.82 (1H, t, J = 7.6 Hz), 6.97 (1H, t, J = 7.6 Hz), 7.02 (2H, d, J = 8.6 Hz), 7.06 (1H, t, J = 8.1 Hz), 7.27 (1H, d, J = 7.7 Hz), 7.51 (1H, d, J = 8.8 Hz), 8.14 (1H, d, J = 7.4 Hz); 13C NMR (150 MHz, CDCl3) δ14.1 (CH3), 22.7 (CH2x2), 28.1 (CH2), 29.3 (CH2x2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 31.9 (CH2), 33.6 (CH), 104.5 (C), 113.2 (C), 115.0 (CH, JC-F = 20.8 Hz), 115.9 (CH, JC-F = 22.1 Hz), 116.8 (CH), 117.4 (C), 120.0 (C), 123.2 (CH), 124.5 (CH, JC-F = 3.1 Hz), 124.8 (CH), 130.2 (CH, JC-F = 9.0 Hz), 133.1 (CH), 143.0 (C), 147.7 (C), 151.2 (C), 152.6 (C), 154.5 (C), 160.2 (C), 162.9 (C, JC-F = 246.1 Hz), 179.3 (C), 181.4 (C); EIMS m/z (%) 544 (M+, 100), 450 (16), 404 (12), 309 (12), 307 (9), 279 (5); HREIMS 544.2240 (calcd for C33H33O6F (M+) 544.2261); IR (CHCl3) νmax 2924, 2852, 2288, 2167, 1699, 1638, 1613, 1561, 1492, 1454, 1376, 1329, 1233, 1188 cm−1.

3.20. 9-hydroxy-7-(4-nitrophenyl)-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4e)

Following the general procedure described above, 24.8 mg (64%) of 4e were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ: 1.11 (3H, t, J = 6.1 Hz), 1.48 (16H, bs), 1.84 (2H, t, J = 7.0 Hz), 2.79 (2H, t, J = 6.3 Hz), 5.06 (1H, s), 6.83 (1H, s), 7.00 (1H, t, J = 7.6 Hz), 7.06 (1H, d, J = 8.1 Hz), 7.12 (1H, t, J = 7.3 Hz), 7.27 (2H, d, J = 8.3 Hz), 7.89 (2H, d, J = 8.2 Hz), 8.18 (1H, d, J = 7.8 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 22.7 (CH2x2), 28.0 (CH2), 29.3 (CH2x2), 29.5 (CH2x2), 29.6 (CH2x2), 31.9 (CH2), 34.1 (CH), 103.9 (C), 112.9 (C), 116.8 (C), 116.9 (CH), 120.5 (C), 123.3 (CH), 123.9 (CHx2), 125.0 (CH), 129.9 (CHx2), 133.5 (CH), 147.5 (C), 147.6 (C), 147.9 (C), 151.3 (C), 152.8 (C), 154.7 (C), 160.2 (C), 179.1 (C), 181.4 (C); EIMS m/z (%) 571 (M+, 100), 450 (20), 449 (44), 431 (20), 309 (14), 306 (11); HREIMS 571.2201 (calcd for C33H33O8N(M+) 571.2206); IR (CHCl3) νmax 2923, 2852, 1718, 1639, 1612, 1557, 1517, 1458, 1345, 1294, 1229, 1184, 1102 cm−1.

3.21. 7-(3-fluoro-4-methoxyphenyl)-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4f)

Following the general procedure described above, 25.3 mg (65%) of 4f were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 6.1 Hz), 1.48 (16H, s), 1.81 (2H, t, J = 6.6 Hz), 2.75 (2H, m), 3.36 (3H, s), 5.15 (1H, s), 6.57 (1H, t, J = 8.6 Hz), 6.85 (1H, s), 6.98 (1H, t, J = 7.6 Hz), 7.05 (1H, d, J = 8.4 Hz), 7.08 (1H, dd, J = 7.4, 1.1 Hz), 7.29 (1H, d, J = 7.5 Hz), 7.45 (1H, d, J = 10.9 Hz), 8.16 (1H, d, J = 7.9 Hz); 13C NMR (150 MHz, DMSO-d6) δ: 14.4 (CH3), 22.5 (CH2), 22.7 (CH2), 28.4 (CH2), 29.1 (CH2), 29.4 (CH2x2), 29.5 (CH2x2), 29.6 (CH2), 31.7 (CH2), 33.3 (CH), 56.3 (CH3), 104.9 (C), 113.7 (C), 113.9 (C), 116.6 (C), 116.9 (CH), 117.1 (CH), 118.1 (CH, JC-F= 4.2 Hz), 123.1 (CH), 125.4 (CH), 125.5 (CH), 133.5 (CH), 135.2 (C), 146.7 (C), 147.8 (C), 151.0 (C), 151.5 (C, JC-F= 242.6 Hz), 152.4 (C), 154.2 (C), 160.3 (C), 177.7 (C), 183.3 (C); EIMS m/z (%) 574 (M+, 100), 450 (17), 449 (20), 448 (23), 435 (23), 434 (48), 323 (14), 309 (36); HREIMS 574.2330 (calcd for C34H35O7F (M+) 574.2367); IR (CHCl3) νmax 3344, 2924, 2853, 2482, 1721, 1639, 1612, 1558, 1517, 1456, 1394, 1337, 1283, 1232, 1184, 1123 cm−1.

3.22. 7-(3,4-dimethoxyphenyl)-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4g)

Following the general procedure described above, 27.1 mg (68 %) of 4g were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 0.91 (3H, t, J = 6.6 Hz), 1.28 (16H, bs), 1.64 (2H, m), 2.60 (2H, m), 3.32 (3H, s), 3.45 (3H, s), 5.04 (1H, s), 6.44 (1H, m), 6.74 (1H, m), 6.79 (1H, m), 6.87 (1H, t, J = 7.1 Hz), 6.91 (1H, d, J = 8.5 Hz), 7.29 (1H, s), 8.02 (1H, d, J = 6.8 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3, C-24), 22.6 (CH2, C-14), 22.7 (CH2, C-23), 28.2 (CH2, C-15), 29.3 (CH2, C-16), 29.4 (CH2, C-17), 29.6 (CH2, C-18), 29.7 (CH2 x4), 31.9 (CH2), 33.3 (CH), 55.8 (CH3), 56.1 (CH3), 105.1 (C), 111.1 (CH), 112.6 (C), 113.3 (C), 116.8 (CH), 120.7 (CH), 123.1 (CH), 124.7 (CH), 128.9 (C), 131.3 (C), 132.8 (CH), 133.5 (CH), 147.4 (C), 148.6 (C), 148.8 (C), 151.4 (C), 152.5 (C), 154.0 (C), 160.5 (C), 179.5 (C), 181.9 (C); EIMS m/z (%): 586 (M+, 100), 492 (12), 450 (33), 429 (17), 428 (88), 342 (14), 310 (62), 288 (14); HREIMS: 586.2584 (calcd for C35H38O8(M+) 586.2567); IR (CHCl3) νmax 2922, 2952, 1713, 1631, 1559, 1514, 1455, 1330, 1268, 1230, 1143, 1048, 1025 cm−1.

3.23. 7-(benzo[d][1,3]dioxo-5-yl)-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4h)

Following the general procedure described above, 22.9 mg (59%) of 4h were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 5.4 Hz), 1.50 (16H, bs), 1.81 (2H, m), 2.75 (2H, d, J = 8.7 Hz), 5.13 (1H, s), 5.37 (2H, d, J = 8.8 Hz), 5.38 (1H, s), 6.70 (1H, d, J = 7.1 Hz), 6.94 (1H, d, J = 9.3 Hz), 6.99 (1H, d, J = 7.4 Hz), 7.03 (1H, d, J = 8.0 Hz), 7.08 (1H, d, J = 8.0 Hz), 7.56 (1H, s), 8.17 (1H, d, J = 9.2 Hz); 13C NMR (150 MHz, DMSO-d6) δ14.4 (CH3), 22.6 (CH2), 22.7 (CH2), 28.3 (CH2), 29.1 (CH2), 29.4 (CH2x2), 29.5 (CH2x2), 29.6 (CH2), 31.7 (CH2), 33.7 (CH), 101.5 (CH2), 105.2 (C), 108.4 (CH), 109.9 (CH), 113.7 (C), 117.0 (C), 117.1 (CH), 118.1 (C), 122.6 (CH), 123.0 (CH), 125.4 (CH), 129.2 (C), 131.8 (C), 133.5 (CH), 136.2 (C), 146.8 (C), 147.6 (C), 152.3 (C), 154.1 (C), 160.4 (C), 177.9 (C), 183.0 (C, C-8); EIMS m/z (%) 570 (M+, 100), 450 (22), 449 (13), 430 (16), 429 (50), 320 (14), 309 (36), 306 (12); HREIMS 570.2260 (calcd for C34H34O8 (M+) 570.2254); IR (CHCl3) νmax 2921, 2852, 1706, 1635, 1559, 1490, 1442, 1329, 1293, 1229, 1187, 1102, 1040 cm−1.

3.24. 9-hydroxy-7-phenyl-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4i)

Following the general procedure described above, 22.1 mg (62%) of 4i were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 0.91 (3H, t, J = 5.6 Hz), 1.28 (16H, bs), 1.60 (2H, t, J = 7.5 Hz), 2.54 (2H, d, J = 6.6 Hz), 5.03 (1H, s), 6.57 (1H, s), 6.80 (2H, t, J = 7.1 Hz), 6.88 (1H, d, J = 7.9 Hz), 6.95 (1H, t, J = 7.2 Hz), 7.04 (2H, t, J = 7.9 Hz), 7.42 (2H, d, J = 7.0 Hz), 7.98 (1H, d, J = 6.7 Hz); 13C NMR (100 MHz, CDCl3) δ: 14.1 (CH3), 22.7 (CH2x2), 28.1 (CH2, C-22), 29.3 (CH2x2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 31.9 (CH2), 33.8 (CH), 105.2 (C), 113.3 (C), 116.8 (CH), 117.9 (C), 119.8 (C), 123.2 (CH), 124.7 (CH), 127.9 (CH), 128.7 (CHx4), 132.9 (CH), 140.7 (C), 147.7 (C), 151.2 (C), 152.6 (C), 154.3 (C), 160.2 (C), 179.5 (C), 181.5 (C); EIMS m/z (%) 526 (M+, 100), 449 (19), 448 (10), 387 (17), 386 (34), 310 (18), 280 (8); HREIMS: 526.2353 (calcd for C33H34O6 (M+) 526.2355); IR (CHCl3) νmax 2924, 2853, 1701, 1637, 1614, 1556, 1455, 1375, 1329, 1296, 1231, 1186, 1099, 1048 cm−1.

3.25. 7-hexyl-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4j)

Following the general procedure described above, 24.7 mg (68%) of 4j were obtained as an amorphous violet solid. 1H NMR (400 MHz, CD3OD) δ: 0.79 (3H, t, J = 5.6 Hz), 0.88 (3H, t, J = 6.2 Hz), 1.24 (26H, bs), 1.80 (2H, m), 2.40 (2H, m), 4.0 (1H, s), 7.38 (1H, d, J = 7.9 Hz), 7.45 (1H, t, J = 7.6 Hz), 7.68 (1H, t, J = 7.9 Hz), 8.19 (1H, d, J = 7.1 Hz); 13C NMR (100 MHz, CDCl3) δ 14.0 (CH3), 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 25.1 (CH2), 28.1 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x2), 29.7 (CH2), 31.7 (CH2), 31.9 (CH2), 32.7 (CH), 104.6 (C), 113.5 (C), 116.8 (CH), 117.9 (C), 119.7 (C), 123.1 (CH), 124.6 (CH), 132.8 (CH), 149.4 (C), 151.3 (C), 152.5 (C), 155.8 (C), 160.9 (C), 179.3 (C), 182.0 (C); EIMS m/z (%) 534 (M+, 0.10), 451 (26), 449 (M+-C6H13, 100), 323 (4), 310 (16), 308 (8); HREIMS 534.2932 (calcd for C33H42O6(M+) 534.2981); IR (CHCl3) νmax 3350, 2925, 2855, 1720, 1641, 1611, 1555, 1458, 1390, 1346, 1288, 1235, 1185 cm−1.

3.26. 9-hydroxy-7-propyl-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4k)

Following the general procedure described above, 12.0 mg (37%) of 4k were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ: 0.87 (6H), 1.25 (18H, bs), 1.44 (2H, m), 1.77 (2H, t, J = 16.6 Hz), 2.41 (2H, m), 4.01 (1H, s), 7.40 (1H, d, J = 8.4 Hz), 7.45 (1H, t, J = 8.0 Hz), 7.69 (1H, t, J = 8.1 Hz), 8.19 (1H, d, J = 7.0 Hz); EIMS m/z (%) 492 (M+, 1), 450 (56), 449 (M+-C3H7, 100), 421 (4), 310 (11); HREIMS 492.2517 (calcd for C30H36O6 (M+) 492.2512); IR (CHCl3) νmax 2930, 2859, 2491, 1725, 1642, 1612, 1560, 1461, 1394, 1340, 1290, 1243, 1189, 1092 cm−1.

3.27. 7-ethyl-9-hydroxy-10-undecylchromeno[4,3-b]chromene-6,8,11(7H)-trione (4l)

Following the general procedure described above, 12.7 mg (39%) of 4l were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ 0.78 (3H, t, J = 6.9 Hz), 0.87 (3H, t, J = 5.8 Hz), 1.25 (16H, bs), 1.51 (2H, t, J = 7.4 Hz), 1.82 (1H, m), 2.00 (1H, m), 2.50 (2H, t, J = 8.3 Hz), 4.19 (1H, t, J = 5.6 Hz), 7.14 (1H, s), 7.38 (2H, t, J = 7.3, 7.7 Hz), 7.61 (1H, t, J = 7.4 Hz), 8.01 (1H, d, J = 7.7 Hz); 13C NMR (100 MHz, CDCl3) δ 9.1 (CH3), 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 25.1 (CH2), 28.1 (CH2), 28.9 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x2), 29.6 (CH2), 31.9 (CH), 103.9 (C), 113.3 (C), 116.7 (CH), 117.5 (C), 119.7 (C), 122.9 (CH), 124.7 (CH), 132.7 (CH), 149.6 (C), 151.2 (C), 152.5 (C), 156.0 (C), 160.9 (C), 179.4 (C), 182.0 (C); EIMS m/z (%) 492 (M+, 0.04), 450 (33), 449 (M+-C2H5, 100), 421 (5), 310 (11), 309 (8); HREIMS: 478.2361 (calcd for C29H34O6 (M+) 478.2355); IR (CHCl3) νmax 3352, 2924, 2853, 1721, 1640, 1611, 1458, 1390, 1347, 1288, 1233, 1185, 1114, 1036 cm−1.

3.28. General Procedures for the Multicomponent Reaction between Embelin (1), Aldehyde (2), And 2-Naphthol (5), with Indium Trichloride as Catalyst

Embelin (1) (20.0 mg, 0.068 mmol), the corresponding aldehyde (2) (0.068 mmol), and 2-naphthol (5) (1.0 mmol) were grinded in a mortar for 5 min. Then, 3.1 mg of InCl3 (20 mol %) was added and the reaction mixture was grinded again for 15 min, placed in a sealed tube and kept in an oven at 120 °C for 1.5 h. The resulting crude was purified by preparative-TLC chromatography using toluene: EtOAc (9:1) as eluant.

3.29. 12-(4-bromophenyl)-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5a)

Following the general procedure described above, 26.0 mg (65%) of 5a were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 6.2 Hz), 1.47 (16H, bs), 1.80 (2H, t, J = 6.5 Hz), 2.76 (2H, q, J = 6.7 Hz), 5.70 (1H, s), 7.05 (1H, s), 7.19 (2H, d, J = 8.5 Hz), 7.23 (2H, d, J = 8.5 Hz), 7.30 (2H, t, J = 10.8, 7.7 Hz), 7.50 (1H, d, J = 9.0 Hz), 7.55 (1H, d, J = 8.9 Hz), 7.66 (1H, d, J = 8.1 Hz), 7.92 (1H, d, J = 8.4 Hz); 13C NMR (100 MHz, CDCl3) δ 14.0 (CH3, C-23), 22.6 (CH2), 22.7 (CH2), 28.0 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 34.8 (CH), 115.1 (C), 115.7 (C), 117.5 (CH), 119.2 (C), 121.2 (C), 123.3 (CH), 125.6 (CH), 127.5 (CH), 128.7 (CH), 130.0 (CH), 130.4 (CHx2), 130.6 (C), 131.8 (CHx2), 132.0 (C), 141.8 (C), 147.5 (C), 149.3 (C), 151.1 (C), 180.5 (C), 182.1 (C); EIMS m/z (%) 586 (M+, 1), 447 (18), 445 (15), 433 (22), 432 (33), 431 (M+-C6H4Br, 100), 403 (4), 303 (10), 292 (13), 291 (12), 289 (11); HREIMS 588.1680 (calcd for C34H35O481Br (M+) 588.1698), 586.1752 (calcd for C34H35O479Br (M+) 586.1719); IR (CHCl3) νmax 2923, 2852, 1630, 1593, 1516, 1463, 1394, 1327, 1214, 1177, 1115, 1072, 1009, 974, 814 cm−1.

3.30. 12-(4-chlorophenyl)-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5b)

Following the general procedure described above, 44.0 mg (81 %) of 5b were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ: 1.11 (3H, t), 1.47 (16H, bs), 1.79 (2H, m), 2.75 (2H, q, J = 6.6 Hz), 5.73 (1H, s), 6.99 (1H, s), 7.08 (2H, d, J = 8.2 Hz), 7.27 (2H, d, J = 8.2 Hz), 7.33 (2H, t, J = 7.5 Hz), 7.50 (1H, d, J = 8.9 Hz), 7.55 (1H, d, J = 8.4 Hz), 7.66 (1H, d, J = 8.0 Hz), 7.91 (1H, d, J = 8.2 Hz); 13C NMR (100 MHz, DMSO-d6) δ 14.0 (CH3), 22.6 (CH2), 22.7 (CH2), 28.0 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 34.8 (CH), 115.1 (C), 115.7 (C), 117.5 (CH), 119.2 (C), 121.2 (C), 123.3 (CH), 125.6 (CH), 127.5 (CH), 128.7 (CH), 130.0 (CH), 130.4 (CHx2), 130.6 (C), 131.8 (CHx2), 132.0 (C), 141.8 (C), 147.5 (C), 149.3 (C), 151.1 (C), 180.5 (C), 182.1 (C); EIMS m/z (%) 542 (M+, 1), 433 (19), 432 (49), 431 (M+-C6H4Cl, 100), 404 (16), 403 (21), 402 (21), 401 (36), 303 (16), 292 (21), 288 (19); HREIMS 544.2135 (calcd for C34H35O437Cl (M+) 544.2194), 542.2208 (calcd for C34H35O435Cl (M+) 542.2224); IR (CHCl3) νmax 2929, 2858, 1635, 1598, 1520, 1493, 1467, 1399, 1330, 1216, 1182, 1093, 977, 825, 745 cm−1.

3.31. 12-(4-fluorophenyl)-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5c)

Following the general procedure described above, 21.5 mg (60%) of 5c were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ: 1.11 (3H, t, J = 6.0 Hz), 1.47 (16H, bs), 1.78 (2H, t, J = 7.2 Hz), 2.74 (2H, q, J = 7.4 Hz), 5.77 (1H, s), 6.77 (2H, t, J = 8.6 Hz), 6.99 (1H, s), 7.32 (4H, dd, J = 8.8, 4.0 Hz), 7.51 (1H, d, J = 8.8 Hz), 7.55 (1H, d, J = 8.8 Hz), 7.66 (1H, d, J = 7.8 Hz), 7.95 (1H, d, J = 8.4 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2x2), 31.9 (CH2), 34.6 (CH), 115.4 (C), 115.6 (CHx2, JC-F = 21.4 Hz), 116.0 (C), 117.6 (CH), 119.1 (C), 123.4 (CH), 125.6 (CH), 127.4 (CH), 128.7 (CH), 129.9 (CH), 130.3 (CHx2, JC-F = 8.0 Hz), 130.7 (C), 132.0 (C), 138.6 (C), 147.5 (C), 149.2 (C), 151.2 (C), 161.7 (C, JC-F = 245.2 Hz), 180.7 (C), 182.2 (C); EIMS m/z (%) 526 (M+, 1), 508 (34), 433 (13), 432 (41), 431 (M+-C6H4F, 100), 387 (15), 386 (25), 302 (13), 292 (15), 289 (13), 280 (16), 268 (13), 230 (17), 218 (11); HREIMS 526.2542 (calcd for C34H35O4F (M+) 526.2519); IR (CHCl3) νmax 2928, 2857, 2475, 1621, 1598, 1509, 1467, 1393, 1320, 1228, 1182, 1073, 1048, 975, 834, 818, 746 cm−1.

3.32. 12-(3-fluorophenyl)-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5d)

Following the general procedure described above, 22.9 mg (64%) of 5d were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 7.2 Hz), 1.48 (16H, bs), 1.76 (2H, t, J = 7.0 Hz), 2.72 (2H, d, J = 8.0 Hz), 5.79 (1H, s), 6.69 (1H, t, J = 8.4 Hz), 6.84 (1H, q, J = 6.4 Hz), 6.97 (1H, s), 7.13 (1H, d, J = 8.2 Hz), 7.28 (2H, t, J = 8.1 Hz), 7.48 (1H, d, J = 8.7 Hz), 7.53 (2H, d, J = 8.8 Hz), 7.64 (1H, d, J = 8.0 Hz), 7.93 (1H, d, J = 8.1 Hz); 13C NMR (100 MHz, CDCl3) δ 14.0 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 31.9 (CH2), 35.0 (CH), 114. 2 (CH, JC-F= 20.6 Hz), 115.8 (CH, JC-F = 20.9 Hz), 117.6 (CH), 119.2 (C), 123.4 (CH), 124.3 (CH, JC-F= 2.6 Hz), 125.6 (CH), 127.5 (CH, JC-F = 9.4 Hz), 127.8 (C), 128.0 (C), 128.7 (CH), 130.0 (CH), 130.1 (CH), 130.7 (C), 132.0 (C), 145.1 (C, JC-F = 5.78 Hz), 147.6 (C), 149.4 (C), 151.2 (C), 162.9 (C, JC-F= 245.8 Hz), 180.5 (C), 182.0 (C); EIMS m/z (%) 526 (M+, 1), 434 (12), 433 (26), 432 (78), 431 (M+-C6H4F, 100), 388 (10), 387 (25), 386 (24), 302 (13), 292 (16), 289 (10), 275 (6), 263 (8); HREIMS 526.2496 (calcd for C34H35O4F(M+) 526.2519); IR (CHCl3) νmax 2925, 2854, 2480, 1616, 1591, 1448, 1323, 1237, 1211, 1124, 1073, 975, 864, 820 cm−1.

3.33. 10-hydroxy-12-(4-nitrophenyl)-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5e)

Following the general procedure described above, 32.7 mg (87 %) of 5e were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ 0.87 (3H, t, J = 6.3 Hz), 1.24 (16H, bs), 1.47 (2H, m, J = 6.9 Hz), 2.46 (2H, t, J = 7.3 Hz), 5.93 (1H, s), 7.13 (1H, s), 7.46 (2H, t, J = 7.4, 3.6 Hz), 7.53 (2H, d, J = 8.4 Hz), 7.58 (1H, d, J = 9.0 Hz), 7.76 (1H, d, J = 8.0 Hz), 7.85 (1H, d, J = 6.7 Hz), 7.89 (1H, d, J = 9.0 Hz), 8.08 (2H, d, J = 8.4 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 35.4 (CH), 114.3 (C), 114.9 (C), 117.6 (CH), 119.6 (C), 123.1 (CH), 123.9 (CHx2), 125.8 (CH), 127.8 (CH), 128.9 (CH), 129.7 (CHx2), 130.5 (CH), 130.9 (C), 132.1 (C), 146.9 (C), 147.6 (C), 149.7 (C), 151.2 (C), 180.2 (C), 181.9 (C); EIMS m/z (%) 553 (M+, 100), 432 (27), 431 (M+-C6H4NO2, 81), 414 (20), 413(29), 302 (13), 291(15), 290 (12). HREIMS: 553.2459 (calcd. for C34H35O6N(M+) 553.2464). IR (CHCl3) νmax: 3339, 2925, 2854, 1631, 1594, 1516, 1463, 1343, 1213, 1179, 1113, 1072, 976 cm−1.

3.34. 12-(3-fluoro-4-methoxyphenyl)-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5f)

Following the general procedure described above, 30.6 mg (81%) of 5f were obtained as an amorphous violet solid. Twenty milligrams of embelin (0.068 mmol), 9.79 mg (0.068 mmol) of 2-naphthol and 10.58 mg of 3-fluoro-4-methoxybenzaldehyde (0.068 mmol) were grinded for 5 min, then 3.1 mg (20 mol %) of InCl3 was added and the reaction mixture was grinded again for 15 min. After 1.5 h at 120 °C, the resulting crude was purified by preparative-TLC using toluene: EtOAc (9:1) as eluant, to provide 1H NMR (400 MHz, C6D6) δ: 1.11 (3H, t, J = 6.2 Hz), 1.47 (16H, bs), 1.78 (2H, t, J = 6.8 Hz), 2.75 (2H, d, J = 6.7 Hz), 3.26 (3H, s), 5.77 (1H, s), 6.39 (1H, t, J = 8.5 Hz), 7.01 (1H, d, J = 8.2 Hz), 7.31 (2H, m, J = 7.8 Hz), 7.51 (1H, d, J = 8.8 Hz), 7.55 (1H, d, J = 4.8 Hz), 7.58 (1H, dd, J = 8.4, 0.9 Hz), 7.67 (1H, d, J = 8.0 Hz), 7.99 (1H, d, J = 8.3 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 34.3 (CH), 56.1 (CH3), 113.2 (C), 115.2 (C), 115.8 (C), 116.5 (CH, JC-F= 18 Hz), 117.6 (CH), 119.1 (C), 123.4 (CH), 124.3 (CH, JC-F = 1.8 Hz), 125.5 (CH), 127.4 (CH, JC-F = 4 Hz), 128.7 (CH), 129.9 (CH), 130.7 (CH), 130.9 (C), 132.0 (C), 135.8 (C), 146.6 (C, JC-F = 8.8 Hz), 147.5 (C), 149.2 (C), 151.2 (C), 152.2 (C, JC-F = 244.7 Hz), 180.7 (C), 182.2 (C); EIMS m/z (%) 556 (M+, 100), 433 (13), 432 (29), 431 (M+-C7H6O1F, 65), 415 (28), 413(29), 304 (19), 302 (16), 291(26), 290 (14), 289 (13), 288 (22), 263 (11); HREIMS 556.2629 (calcd. for C35H37O5F (M+) 556.2625). IR (CHCl3) νmax 2930, 2858, 1635, 1598, 1518, 1466, 1443, 1331, 1275, 1214, 1122, 1075, 978 cm−1.

3.35. 12-(3,4-dimethoxyphenyl)-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5g)

Following the general procedure described above, 32.1 mg (83%) of 5g were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ: 0.87 (3H, t), 1.25 (16H, bs), 1.47 (2H, t, J = 9.2 Hz), 2.45 (2H, t, J = 7.0 Hz), 3.76 (3H, s), 3.79 (3H, s), 5.75 (1H, s), 6.69 (1H, d, J = 8.2 Hz), 6.80 (1H, d, J = 7.9 Hz), 6.92 (1H, s), 7.19 (1H, s), 7.44 (2H, m), 7.54 (1H, d, J = 8.9 Hz), 7.83 (2H, t, J = 8.4 Hz), 7.89 (1H, d, J = 7.8 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2x2), 31.9 (CH2), 34.8 (CH), 55.8 (CH3), 55.9 (CH3), 111.2 (CH), 112.0 (CH), 115.8 (C), 116.3 (C), 117.5 (CH), 119.0 (C), 121.1 (CH), 123.6 (CH), 125.5 (CH), 127.3 (CH), 128.6 (CH), 128.8 (C), 129.7 (CH), 130.9 (C), 131.9 (C), 135.5 (C), 147.6 (C), 148.0 (C), 149.1 (C), 151.2 (C), 180.8 (C), 182.4 (C); EIMS m/z (%) 568 (M+, 100), 432 (17), 431 (M+-C8H9O2, 27), 428 (18), 317 (14), 292 (14), 288 (10); HREIMS: 568.2806 (calcd. for C36H40O6(M+) 568.2825). IR (CHCl3) νmax 2926, 2854, 1635, 1594, 1513, 1461, 1328, 1266, 1231, 1140, 1072, 1026, 812 cm−1.

3.36. 12-(benzo[d]dioxo-5-yl)-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5h)

Following the general procedure described above, 33.0 mg (88%) of 5h were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 5.9 Hz), 1.47 (16H, bs), 1.77 (2H, m), 2.74 (2H, d, J = 4.9 Hz), 5.29 (2H, dd, J = 5.9, 4.2 Hz), 5.79 (1H, s), 6.59 (1H, d, J = 7.7 Hz), 6.93 (1H, d, J = 8.2 Hz), 7.06 (1H, d, J = 8.9 Hz), 7.24 (1H, s), 7.31 (1H, d, J = 7.8 Hz), 7.50 (2H, m), 7.66 (1H, d, J = 7.8 Hz), 8.08 (1H, d, J = 8.5 Hz); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2, C-22), 22.7 (CH2, C-13), 28.1 (CH2, C-14), 29.3 (CH2, C-15), 29.4 (CH2, C-16), 29.5 (CH2, C-17), 29.6 (CH2x2), 29.7 (CH2), 31.9 (CH2), 34.9 (CH), 101.1 (CH2), 108.2 (CH), 109.1 (CH), 115.7 (C), 116.3 (C), 117.6 (CH), 119.1 (C), 122.1 (CH), 123.5 (CH), 125.5 (CH), 127.3 (CH), 128.7 (CH), 129.7 (CH), 130.8 (C), 131.9 (C), 136.8 (C), 146.5 (C), 147.4 (C), 147.9 (C), 149.3 (C), 153.2 (C), 180.8 (C), 182.4 (C); EIMS m/z (%) 552 (M+, 100), 430 (M+-C7H5O2, 10), 413(11), 412 (34), 330 (4), 300(30), 292 (18), 291 (18), 230(14); HREIMS 552.2494 (calcd for C35H36O6 (M+) 552.2512); IR (CHCl3) νmax 2924, 2853, 1626, 1554, 1486, 1441, 1395, 1329, 1213, 1174, 1116, 1037, 973, 926, 810, 744 cm−1.

3.37. 10-hydroxy-12-phenyl-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5i)

Following the general procedure described above, 28.3 mg (82 %) of 5i were obtained as an amorphous violet solid. 1H NMR (400 MHz, C6D6) δ 1.11 (3H, t, J = 5.5 Hz), 1.48 (16H, bs), 1.76 (2H, t, J = 7.2 Hz), 2.71 (2H, d, J = 8.7 Hz), 5.87 (1H, s), 7.02 (1H, t, J = 6.8 Hz), 7.14 (2H, t, J = 7.2 Hz), 7.27 (1H, t, J = 7.7 Hz), 7.32 (1H, d, J = 7.7 Hz), 7.56 (3H, t, J = 7.6 Hz), 7.65 (1H, d, J = 7.6 Hz), 8.06 (1H, d, J = 8.3 Hz); EIMS m/z (%): 508 (M+, 0.99), 434 (3), 433 (12), 432 (35), 431 (M+-C6H5, 100), 369 (9), 368 (17), 302 (11), 292 (12). HREIMS: 508.2594 (calcd. para C34H36O4(M+) 508.2614). IR (CHCl3) νmax: 2922, 2851, 1631, 1511, 1385, 1356, 1330, 1218, 1176, 1116, 1078, 975, 751cm−1.

3.38. 12-hexyl-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5j)

Following the general procedure described above, 15.8 mg (45 %) of 5j were obtained as an amorphous violet solid. 1H NMR (500 MHz, C6D6) δ 0.87 (3H, t, J = 7.2 Hz), 1.06 (2H, m), 1.11 (3H, t, J = 6.6 Hz), 1.24 (2H, m), 1.38 (2H, m), 1.48 (16H, bs), 1.60 (2H, m), 1.87 (2H, t, J = 6.9 Hz), 2.01 (2H, m), 2.85 (2H, t, J = 8.5 Hz), 4.90 (1H, t, J = 4.9 Hz), 7.41 (2H, m), 7.50 (2H, d, J = 8.8 Hz), 7.71 (1H, d, J = 8.0 Hz), 7.95 (1H, d, J = 8.1 Hz); 13C NMR (100 MHz, CDCl3) δ 13.9 (CH3), 14.1 (CH3), 22.5 (CH2), 22.7 (CH2x2), 24.9 (CH2t, C-14), 28.2 (CH2), 28.6 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.6 (CH2), 29.7 (CH2x3), 31.6 (CH2), 34.9 (CH), 115.7 (C), 116.4 (C), 117.4 (CH), 118.9 (C), 122.9 (CH), 125.3 (CH), 127.1 (CH), 128.8 (CHx2), 130.6 (C), 131.9 (C), 148.2 (C), 151.2 (C), 151.7 (C), 180.6 (C), 182.5 (C); EIMS m/z (%) 516 (M+, 0.05), 433 (16), 432 (41), 431 (M+-C6H13, 100), 334 (27), 317 (19), 292 (12), 291 (13), 277 (27), 263 (20). HREIMS 516.3255 (calcd for C34H44O4(M+) 516.3240); IR (CHCl3) νmax 3347, 2927, 2857, 1633, 1596, 1521, 1466, 1332, 1276, 1209, 1119, 973, 819, 742 cm−1.

3.39. 10-hydroxy-12-propyl-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5k)

Following the general procedure described above, 15.8 mg (49%) of 5k were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ: 0.74 (3H, t, J= 7.1 Hz), 0.87 (3H, t, J = 6.2 Hz), 0.95 (2H, m), 1.26 (16H, bs), 1.52 (2H, t, J = 7.7 Hz), 1.82 (2H, m), 2.50 (2H, t, J = 7.2 Hz), 4.83 (1H, t, J = 4.8 Hz), 7.41 (1H, d, J = 8.9 Hz), 7.49 (1H, t, J = 7.5 Hz), 7.59 (1H, t, J = 7.2 Hz), 7.76 (1H, d, J = 8.9 Hz), 7.85 (1H, d, J = 8.0 Hz), 8.05 (1H, d, J = 8.4 Hz); 13C NMR (100 MHz, CDCl3) δ 13.9 (CH3), 14.1 (CH3), 18.3 (CH2), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 28.6 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2x3), 31.9 (CH2), 37.2 (CH), 115.8 (C), 116.5 (C), 117.4 (CH), 118.9 (C), 122.9 (CH), 125.4 (CH), 127.1 (CH), 128.8 (CHx2), 130.7 (C), 131.9 (C), 148.2 (C), 151.2 (C), 151.8 (C), 180.6 (C), 182.5 (C); EIMS m/z (%) 474 (M+, 1), 433 (8), 432 (31), 431 (M+-C3H7, 100), 389 (7), 302 (7), 292 (8); HREIMS 474.2762 (calcd. for C31H38O4(M+) 474.2770); IR (CHCl3) νmax 2928, 2857, 1635, 1597, 1522, 1465, 1363, 1335, 1276, 1213, 1179, 1118, 1084 cm−1.

3.40. 12-ethyl-10-hydroxy-9-undecyl-8H-benzo[a]xanthene-8,11(12H)-dione (5l)

Following the general procedure described above, 10.7 mg (27%) of 5l were obtained as an amorphous violet solid. 1H NMR (400 MHz, CDCl3) δ 0.65 (3H, t, J = 7.1 Hz), 0.87 (3H, t, J = 5.9 Hz), 1.25 (16H, bs), 1.51 (2H, t, J = 8.0 Hz), 1.92 (2H, m), 2.50 (2H, t, J = 6.9 Hz), 4.85 (1H, t, J = 4.0 Hz), 7.41 (1H, d, J = 8.8 Hz), 7.48 (1H, t, J = 7.4 Hz), 7.58 (1H, d, J = 6.4 Hz), 7.77 (1H, d, J = 8.8 Hz), 7.85 (1H, d, J = 7.9 Hz), 8.04 (1H, d, J = 7.9 Hz); 13C NMR (100 MHz, CDCl3) δ 9.0 (CH3), 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2x2), 29.5 (CH2x2), 29.6 (CH2x3), 31.9 (CH), 115.1 (C), 115.8 (C), 117.4 (CH), 118.9 (C), 122.9 (CH), 125.4 (CH), 127.1 (CH), 128.8 (CH), 128.9 (CH), 130.7 (C), 131.9 (C), 148.4 (C), 151.2 (C), 151.9 (C), 180.6 (C), 182.5 (C); EIMS m/z (%) 460 (M+, 1), 433 (13), 432 (36), 431 (M+-C2H5, 100), 302 (5). HREIMS: 460.2610 (calcd for C30H36O4(M+) 460.2614); IR (CHCl3) νmax 3379, 2926, 2856, 1618, 1595, 1465, 1324, 1272, 1228, 1119, 1087, 969, 821 cm−1.

3.41. Biological Assays

Antibacterial activity was determined using the standard broth microdilution method as recommended by the National Committee for Clinical Laboratory Standards [8,11,25]. We used three Gram-positive bacterial strains; methicillin-sensitive Staphylococcus aureus ATCC25923 (MSSA), methicillin-resistant vancomycin-intermediate resistant Staphylococcus aureus NRS402 (VISA), and Enterococcus faecalis ATCC29212; as well as the Gram-negative Escherichia coli ATCC35218. Bacterial strains stored at −80 °C were first plated on brain heart infusion (BHI) agar and incubated at 37 °C overnight followed by a second overnight growth in cation-adjusted Mueller–Hinton (MH) broth. Bacterial suspensions were then normalized in fresh MH broth and added to premade 1:2 serial dilutions of each tested compounds and control antibiotics in the same media. The range of concentrations was from 0.5 to 128 (μM for the tested compounds and μg/mL for the reference antibiotics) and the final volume was 200 μL. The expected initial concentration in all wells was 1 × 105 cells/mL. The minimum inhibitory concentration (MIC) was estimated by eye after 24 h of incubation at 37 °C without shaking.
A similar procedure was used for the yeast Saccharomyces cerevisiae BY4741 wild-type strain [26]. In this case, the growing media was YPD and the inoculum was ~2 × 104 cells/mL. The growth was measured at 30 °C after 24 h and 48 h.

3.42. Calculation of Electrostatic Polar Potentials, Electron Density, and Fukui Indices

The calculations of Density Functional Theory (DFT) was employed for optimization and minimization of geometry of the compounds shown in Scheme 2, as well as to examine the reactivity of the calculated compounds, their structural and electronic properties were obtained by parameters of reactivity and theoretical properties such as the energy values of highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO), electronic density and electrostatic potential using the B3LYP functional and the 6-31+G(d,p) basis set implemented in Jaguar-v.10.6 computational program [27,28]. Atomic Fukui indices were derived from Mulliken population of the highest occupied molecular orbital (HOMO) and the LUMO, were used to quantify electrophilicity of a molecule at a particular atomic site. The default convergence criterion implemented in Jaguar was used for self-consistent field (SCF) calculations (accuracy level = quick, convergence criteria: maximum iteration = 48, and energy change = 5 × 10−5 hartree) and optimization (maximum steps = 100, convergence criteria = default, initial Hessian = Schlegel guess [29,30].

4. Conclusions

In summary, three series of new embelin conjugates were obtained through an InCl3 catalyzed three component reaction from embelin (1), aldehydes and privileged substructures of antimicrobial interest such as 4-hydroxy-2H-pyran-2-one, 4-hydroxy-coumarin, and 2-naphthol. This MCR implies Knoevenagel condensation, Michael addition, intramolecular cyclization, and dehydration. Most part of the conjugates synthesized from 4-hydroxy-2H-pyran-2-one and 4-hydroxy-coumarin resulted to be active and selective toward Gram positive bacteria. Some structure–activity relationships were outlined and the most active compounds were 3a–3c, 4c, 4d, and 4g with MICs around 1–2 μM. The present results encourage further research with these compounds in order to develop novel antibiotic agents against Gram-positive bacteria.

Supplementary Materials

The following are available online 1H NMR and 13C NMR spectra of compounds 3a–3l, 4a–4l and 5a–5l.

Author Contributions

G.F. and A.T. isolated and purified embelin. F.M. and I.L.-C. contributed to the performance of the biological experimental work. R.P. and P.M.-A. prepared, purified and characterized the embelin derivatives. Á.A., carried out the computational studies. A.E.-B., Á.A., and F.M., contributed in the conception, design, discussion of the results, drafting and financial support of the manuscript submitted. All authors read and approved the final version of the manuscript.

Funding

We gratefully acknowledge the financial support from the Spanish MICIU RTI2018-094356-B-C21 to AEB and BFU2017-83954-R to FM, Agencia Canaria de Investigación, Innovación y Sociedad de la Información Pro ID 2017010071 to AEB and ProID2017010167 to FM. These projects are also co-funded by the European Regional Development Fund (FEDER). PIO-CONICET SECITI N° 0022 and CICITCA-UNSJ to GF and AT.

Acknowledgments

PMA thanks to ACIISI for a pre-doctoral grant (FPI-Program). AA thanks the Cabildo de Tenerife (Agustín de Betancourt Program).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kim, J.; Kim, H.; Park, S.B. Privileged structures: Efficient chemical “navigators” toward unexplored biologically relevant chemical spaces. J. Am. Chem. Soc. 2014, 136, 14629–14638. [Google Scholar] [CrossRef] [PubMed]
  2. Heng, Z.; Ge, S.; Gao, M.; Jian, R.; Chen, X.; Xu, X.; Li, D.; Zhang, K.; Chen, W.-H. Synthesis and biological activity of embelin and its derivatives: An overview. Mini-Rev. Med. Chem. 2020, 20, 396–407. [Google Scholar]
  3. Li, J.Y.; Chen, R.J.; Huang, L.T.; Lee, T.Y.; Lu, W.J.; Lin, K.H. Embelin as a novel inhibitor of PKC in the prevention of platelet activation and thrombus formation. J. Clin. Med. 2019, 8, 1724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Nigam, N.; Grover, A.; Goyal, S.; Katiyar, S.P.; Bhargava, P.; Wang, P.C.; Sundar, D.; Kaul, S.C.; Wadhwa, R. Targeting mortalin by embelin causes activation of tumor suppressor p53 and deactivation of metastatic signaling in human breast cancer cells. PLoS ONE 2015, 10, e0138192/1–e0138192/15. [Google Scholar] [CrossRef] [Green Version]
  5. Filosa, R.; Peduto, A.; Schaible, A.M.; Krauth, V.; Weinigel, C.; Barz, D.; Petronzi, C.; Bruno, F.; Roviezzo, F.; Spaziano, G.; et al. Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes. Eur. J. Med. Chem. 2015, 94, 132–139. [Google Scholar] [CrossRef]
  6. Avisetti, D.R.; Babu, K.S.; Kalivendi, S.V. Activation of p38/JNK pathway is responsible for embelin induced apoptosis in lung cancer cells: Transitional role of reactive oxygen species. PLoS ONE 2014, 9, e87050/1–e87050/10. [Google Scholar] [CrossRef]
  7. Naik, S.R.; Niture, N.T.; Ansari, A.A.; Shah, P.D. Anti-diabetic activity of embelin: Involvement of cellular inflammatory mediators, oxidative stress and other biomarkers. Phytomedicine 2013, 20, 797–804. [Google Scholar] [CrossRef]
  8. Peña, R.; Jimenez-Alonso, S.; Feresin, G.; Tapia, A.; Méndez-Alvarez, S.; Machin, F.; Ravelo, A.G.; Estevez-Braun, A. Multicomponent synthesis of antibacterial dihydropyridin and dihydropyran embelin derivatives. J. Org. Chem. 2013, 78, 7977–7985. [Google Scholar]
  9. Martín-Acosta, P.; Haider, S.; Amesty, A.; Aichele, D.; Jose, J.; Estevez-Braun, A. A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors. Eur. J. Med. Chem. 2018, 144, 410–423. [Google Scholar] [CrossRef]
  10. Jiménez-Alonso, S.; Pérez-Lomas, A.L.; Estévez-Braun, A.; Muñoz-Martinez, F.; Chávez-Orellana, H.; Ravelo, A.G.; Gamarro, F.; Castanys, S.; López, M. Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania. J. Med. Chem. 2008, 51, 7132–7143. [Google Scholar]
  11. Peña, R.; Martín-Acosta, P.; Feresin, G.E.; Tapia, A.; Machin, F.; Estevez-Braun, A. Domino synthesis of embelin derivatives with antibacterial activity. J. Nat. Prod. 2016, 79, 970–977. [Google Scholar]
  12. Martín-Acosta, P.; Feresin, G.; Tapia, A.; Estévez-Braun, A. Microwave-assisted organocatalytic intramolecular Knoevenagel/Hetero Diels–Alder reaction with O-(arylpropynyloxy)-salicylaldehydes: Synthesis of polycyclic embelin derivatives. J. Org. Chem. 2016, 81, 9738–9756. [Google Scholar] [CrossRef] [PubMed]
  13. Evans, B.E.; Rittle, K.E.; Bock, M.G.; Dipardo, R.M.; Freidinger, R.M.; Whitter, W.L.; Lundell, G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S.L.; et al. Methods for drug discovery. Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235–2246. [Google Scholar] [CrossRef] [PubMed]
  14. Campanini-Salinas, J.; Campanini-Salinas, J.; Andrades-Lagos, J.; Vasquez-Velasquez, D.; Mella-Raipan, J. Novel classes of antibacterial drugs in clinical development, a hope in a post-antibiotic era. Curr. Top. Med. Chem. 2018, 18, 1188–1202. [Google Scholar] [CrossRef] [PubMed]
  15. Josef, J. Design and discovery of new antibacterial agents: Advances, perspectives, challenges. Curr. Med. Chem. 2018, 25, 4972–5006. [Google Scholar]
  16. Parr, R.G.; Yang, W. Density functional approach to the frontier-electron theory of chemical reactivity. J. Am. Chem. Soc. 1984, 106, 4049–4050. [Google Scholar] [CrossRef]
  17. Yang, W.; Mortier, W.J. The use of global and local molecular parameters for the analysis of the gas-phase basicity of amines. J. Am. Chem. Soc. 1986, 108, 5708–5711. [Google Scholar] [CrossRef]
  18. Kim, M.; Hwang, Y.S.; Cho, W.; Park, S.B. Synthesis of 3,5-disubstituted isoxazoles containing privileged substructures with a diverse display of polar surface area. ACS Comb. Sci. 2017, 19, 407–413. [Google Scholar] [CrossRef]
  19. Jiménez-Alonso, S.; Guasch, J.; Estévez-Braun, A.; Ratera, I.; Veciana, J.; Ravelo, A.G. Electronic and cytotoxic properties of 2-amino-naphtho[2,3-b]furan-4,9-diones. J. Org. Chem. 2011, 76, 1634–1643. [Google Scholar]
  20. Khurana, J.M.; Magoo, D. pTSA-catalyzed one-pot synthesis of 12-aryl-8,9,10,12-tetrahydrobenzo[a] xanthen-11-ones in ionic liquid and neat conditions. Tetrahedron Let. 2009, 50, 4777–4780. [Google Scholar] [CrossRef]
  21. Liu, L.; Sarkisian, R.; Deng, Y.; Wang, H. Sc(OTf)3-Catalyzed Three-component cyclization of arylamines, β,γ-Unsaturated α-Ketoesters, and 1,3-dicarbonyl compounds for the synthesis of highly substituted 1,4-dihydropyridines and tetrahydropyridines. J. Org. Chem. 2013, 78, 5751–5755. [Google Scholar] [CrossRef] [PubMed]
  22. Stefani, H.A.; Manarin, F.; Souza, A.C.S.; Souza, F.B.; Frederico, B.; Ferraz, W.R. Three-component reaction for the synthesis of diverse β-unsaturated α-amino esters. Tetrahedron 2014, 70, 3243–3248. [Google Scholar] [CrossRef]
  23. Hueso-Falcón, I.; Amesty, A.; Martín, P.; López-Rodríguez, M.; Fernández-Pérez, L.; Estévez-Braun, A. Indium catalyzed solvent-free multicomponent synthesis of cytotoxic dibenzo[a,h]anthracenes from aldehydes, 2-hydroxy-1,4-naphthoquinone, and 2-naphthol. Tetrahedron 2014, 70, 8480–8487. [Google Scholar]
  24. Feresin, G.E.; Tapia, A.; Sortino, M.; Zacchino, S.; de Arias, A.R.; Inchausti, A.; Yaluff, J.; Rodriguez, G.; Theoduloz, C.; Schmeda-Hirschmann, G. Bioactive alkyl phenols and embelin from Oxalis erythrorhiza. J. Ethnopharmacol. 2003, 88, 241–247. [Google Scholar] [CrossRef]
  25. Oramas-Royo, S.; Pantoja, K.D.; Amesty, A.; Romero, C.; Lorenzo-Castrillejo, I.; Machín, F.; Estevez-Braun, A. Synthesis and antibacterial activity of new symmetric polyoxygenated dibenzofurans. Eur. J. Med. Chem. 2017, 141, 178–187. [Google Scholar] [CrossRef]
  26. Ramos-Pérez, C.; Lorenzo-Castrillejo, I.; Quevedo, O.; García-Luis, J.; Matos-Perdomo, E.; Medina-Coello, C.; Estévez-Braun, A.; Machín, F. Yeast cytotoxic sensitivity to the antitumour agent β-lapachone depends mainly on oxidative stress and is largely independent of microtubule- or topoisomerase-mediated DNA damage. Biochem. Pharmacol. 2014, 92, 206–219. [Google Scholar]
  27. PCMODEL 9.2; Serena Software: Bloomington, IN, USA, Copyright 1988e2006; Available online: www.serenasoft.com (accessed on 20 July 2020).
  28. Jaguar, Version 7.8; Schrodinger: New York, NY, USA, 2011.
  29. Schlegel, B. Estimating the hessian for gradient-type geometry optimizations. Theor. Chim. Acta 1984, 66, 333–340. [Google Scholar] [CrossRef]
  30. Bochevarov, A.D.; Harder, E.; Hughes, T.F.; Greenwood, J.R.; Braden, D.A.; Philipp, D.M.; Rinaldo, D.; Halls, M.D.; Zhang, J.; Friesner, R.A. Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences. Int. J. Quantum Chem. 2013, 113, 2110–2142. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds 3a–3l, 4a–4l and 5a–5l are available from the authors.
Molecules 25 03290 sch001 550
Scheme 1. Structure of embelin-privileged structure conjugates.
Scheme 1. Structure of embelin-privileged structure conjugates.
Molecules 25 03290 sch001
Molecules 25 03290 g001 550
Figure 1. Location and highest value of the Fukui function (fk−) for compounds (1–4).
Figure 1. Location and highest value of the Fukui function (fk−) for compounds (1–4).
Molecules 25 03290 g001
Molecules 25 03290 sch002 550
Scheme 2. Formation of embelin-conjugates.
Scheme 2. Formation of embelin-conjugates.
Molecules 25 03290 sch002
Molecules 25 03290 sch003 550
Scheme 3. Plausible formation of adducts 3a–3l.
Scheme 3. Plausible formation of adducts 3a–3l.
Molecules 25 03290 sch003
Table
Table 1. Optimization of the MCR of 1, 2 and 4-bromobenzaldehyde.
Table 1. Optimization of the MCR of 1, 2 and 4-bromobenzaldehyde.
EntryConditionsYield (%) *
110 mol% EDDA, DCE, Δ, 24 h-
210 mol% EDDA, EtOH, Δ, 24 h-
330 mol% EDDA, DCE, MW, 120 °C, 30′-
410 mol% InCl3, EtOH, Δ, 3 h32
510 mol% InCl3, neat, 120 °C, 3 h52
610 mol% Sc(OTf)3, neat, 120 °C, 1.5 h32
710 mol% Yb(OTf)3, neat, 120 °C, 1.5 h50
810 mol% PTSA, neat, 120 °C, 1.5 h24
9neat, 120 °C, 3 h11
1020 mol% InCl3, neat, 120 °C, 1.5 h58
1130 mol % InCl3, neat, 120 °C, 1.5 h54
* Isolated yields.
Table
Table 2. Synthesis of novel tricyclic embelin adducts (3a–3l).
Table 2. Synthesis of novel tricyclic embelin adducts (3a–3l).
Molecules 25 03290 i001 Molecules 25 03290 i002 Molecules 25 03290 i003
Molecules 25 03290 i004 Molecules 25 03290 i005 Molecules 25 03290 i006
Molecules 25 03290 i007 Molecules 25 03290 i008 Molecules 25 03290 i009
Molecules 25 03290 i010 Molecules 25 03290 i011 Molecules 25 03290 i012
Molecules 25 03290 i013 Molecules 25 03290 i014 Molecules 25 03290 i015
Table
Table 3. Synthesis of novel embelin–coumarin conjugates (4a–4l).
Table 3. Synthesis of novel embelin–coumarin conjugates (4a–4l).
Molecules 25 03290 i016 Molecules 25 03290 i017 Molecules 25 03290 i018
Molecules 25 03290 i019 Molecules 25 03290 i020 Molecules 25 03290 i021
Molecules 25 03290 i022 Molecules 25 03290 i023 Molecules 25 03290 i024
Molecules 25 03290 i025 Molecules 25 03290 i026 Molecules 25 03290 i027
Molecules 25 03290 i028 Molecules 25 03290 i029 Molecules 25 03290 i030
Table
Table 4. Synthesis of novel tetracyclic embelin adducts (5a–5l).
Table 4. Synthesis of novel tetracyclic embelin adducts (5a–5l).
Molecules 25 03290 i031 Molecules 25 03290 i032 Molecules 25 03290 i033
Molecules 25 03290 i034 Molecules 25 03290 i035 Molecules 25 03290 i036
Molecules 25 03290 i037 Molecules 25 03290 i038 Molecules 25 03290 i039
Molecules 25 03290 i040 Molecules 25 03290 i041 Molecules 25 03290 i042
Molecules 25 03290 i043 Molecules 25 03290 i044 Molecules 25 03290 i045
Table
Table 5. Minimum inhibitory concentration (MIC) for compounds 1, 3a–l, 4a–l, and 5a–l against the three selected Gram-positive bacterial strains.
Table 5. Minimum inhibitory concentration (MIC) for compounds 1, 3a–l, 4a–l, and 5a–l against the three selected Gram-positive bacterial strains.
EntryCompound *S. aureus
(ATCC25923)		S. aureus
(NRS402)		E. faecalis
(ATCC29212)
113232128
23a1<12
33b221
43c221
53d222
63e442
73f222
83g244
93h442
103i442
113j842
123k444
133l882
144a1648
154b224
164c221
174d122
184e222
194f824
204g122
214h224
224i422
234j>128>128>128
244k>128>128>128
254l1286432
265a>128>128>128
275b>128>128>128
285c>1281632
295d>1283232
305e>128>128>128
315f>128>128>128
325g>1281616
335h>128>128>128
345i>1286332
355j>128>128>128
365k>1283232
375l>128328
38ampilicin<1>1288
39oxacillin<1>1288
40vancomycin<144
41mupirocin<1<116
* MICs for tested compounds are in μM and for reference antibiotics are in mg/L.

Share and Cite

MDPI and ACS Style

Martín-Acosta, P.; Peña, R.; Feresin, G.; Tapia, A.; Lorenzo-Castrillejo, I.; Machín, F.; Amesty, Á.; Estévez-Braun, A. Efficient Multicomponent Synthesis of Diverse Antibacterial Embelin-Privileged Structure Conjugates. Molecules 2020, 25, 3290. https://doi.org/10.3390/molecules25143290

AMA Style

Martín-Acosta P, Peña R, Feresin G, Tapia A, Lorenzo-Castrillejo I, Machín F, Amesty Á, Estévez-Braun A. Efficient Multicomponent Synthesis of Diverse Antibacterial Embelin-Privileged Structure Conjugates. Molecules. 2020; 25(14):3290. https://doi.org/10.3390/molecules25143290

Chicago/Turabian Style

Martín-Acosta, Pedro, Rosalyn Peña, Gabriela Feresin, Alejandro Tapia, Isabel Lorenzo-Castrillejo, Félix Machín, Ángel Amesty, and Ana Estévez-Braun. 2020. "Efficient Multicomponent Synthesis of Diverse Antibacterial Embelin-Privileged Structure Conjugates" Molecules 25, no. 14: 3290. https://doi.org/10.3390/molecules25143290

Article Metrics

Back to TopTop